EGFR and non-small cell lung carcinoma: In these previous studies, chemotherapy was the primary systemic therapy combined with local treatment; furthermore, the concurrent use of tyrosine kinase inhibitors (TKI) and SBRT for patients with EGFR-mutated NSCLC was reported in 2023 [8].